



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.   | FILING DATE        | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|---|--------------------|----------------------|-------------------------|------------------|
| 10/043,627  | 01/09/2002         | Xiao-Tao Chen        | PH-7211 6514            |                  |
| 23914   | 7590 04/07/2004    |                      | EXAMINER                |                  |
| STEPHEN B. DAVIS BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000 PRINCETON, NJ 08543-4000 |                    |                      | LIU, HONG               |                  |
|   |                    |                      | ART UNIT                | PAPER NUMBER     |
|   |                    |                      | 1624                    |                  |
| IRINCETO  | 1, 11, 00,043-4000 |                      | DATE MAILED: 04/07/2004 |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|  | Application No.  | Applicant(s)                         |  |  |  |  |
|--|--|--------------------------------------|--|--|--|--|
| Advisory Action  | 10/043,627   | CHEN ET AL.                          |  |  |  |  |
| Advisory Action  | Examiner   | Art Unit                             |  |  |  |  |
|  | Hong Liu   | 1624                                 |  |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address  |  |                                      |  |  |  |  |
| THE REPLY FILED 19 March 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.  |  |                                      |  |  |  |  |
| PERIOD FOR RE  | PLY [check either a) or b)]  |                                      |  |  |  |  |
| a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |  |                                      |  |  |  |  |
| 1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.   |  |                                      |  |  |  |  |
| 2. The proposed amendment(s) will not be entered because:  |  |                                      |  |  |  |  |
| (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);   |  |                                      |  |  |  |  |
| (b) ☐ they raise the issue of new matter (see Note below);   |  |                                      |  |  |  |  |
| (c) \( \sum \) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or  |  |                                      |  |  |  |  |
| (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.  NOTE:   |  |                                      |  |  |  |  |
| Applicant's reply has overcome the following rejection:  | on(e):   |                                      |  |  |  |  |
| 4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).  |  |                                      |  |  |  |  |
| 5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:  |  |                                      |  |  |  |  |
| 6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.   |  |                                      |  |  |  |  |
| 7. For purposes of Appeal, the proposed amendment(s explanation of how the new or amended claims work  | s) a)⊡ will not be entered or b)[<br>uld be rejected is provided belov | will be entered and an vor appended. |  |  |  |  |
| The status of the claim(s) is (or will be) as follows:   |  |                                      |  |  |  |  |
| Claim(s) allowed:  |  |                                      |  |  |  |  |
| Claim(s) objected to: 5.   |  |                                      |  |  |  |  |
| Claim(s) rejected: <u>1-4,6-18 and 27-31</u> .   |  |                                      |  |  |  |  |
| Claim(s) withdrawn from consideration:   |  |                                      |  |  |  |  |
| 8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.   |  |                                      |  |  |  |  |
| 9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)  |  |                                      |  |  |  |  |
| 10. Other:   |  |                                      |  |  |  |  |
|  |  |                                      |  |  |  |  |
|  |  |                                      |  |  |  |  |
|  |  |                                      |  |  |  |  |

Application/Control Number: 10/043,627

Art Unit: 1624

## ADVISORY ACTION

The after final amendment filed on 03/19/04 cannot be entered since the method claims are still not enabled. Applicants provided a number of journal articles to support their arguments that these claims meet the enablement requirements. However, a review of these references reveals no methods of treatment of inflammation in general. For a compound or genus to be effective against inflammation generally is contrary to medical science. Inflammation is a process which can take place in virtually any part of the body. There is a vast range of forms that it can take, causes for the problem, and biochemical pathways that mediate the inflammatory reaction. There is no common mechanism by which all, or even most, inflammations arise. Mediators include bradykinin, serotonin, C3a, C5a, histamine, assorted leukotrienes and cytokines, and many, many others. Accordingly, treatments for inflammation are normally tailored to the particular type of inflammation present, as there is no, and there can be no "magic bullet" against inflammation generally. Since the references submitted by the applicants do not suggest that the compounds can be employed to treat inflammation in general, the claims are stilled deemed not enabled.

Applicants are reminded that entry of amendment after final rejection is not a matter of right. "Except where an amendment merely cancels claims, adopts examiner suggestions, remove issues for appeal, or is some other way only a cursory review by the examiner, compliance with the requirement of a showing under 37 CFR 1.116(b) is expected in all amendments after final reelection." See MPEP 714.13. For these reasons, this amendment after final rejection will not be entered.

Art Unit: 1624

Any inquiry concerning this communication should be directed to Examiner Hong Liu whose telephone number is (571) 272-0669. The examiner can normally be reached on Monday through Friday from 8:30 AM to 6:00 PM.

If attempts to reach the examiner by the phone are unsuccessful, the examiner's supervisors, Mukund Shah can be reached at (571) 272-0674. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 358-1235.

Muximal J. Shor Willow

Mukund Shah Supervisory Patent Examiner Art Unit 1624

hl April 2, 2004